MedTrace Logo

Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)

NCT01373398 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2012-03-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of intravesical instillation of EO9 in patients with non-muscle invasive bladder cancer (NMIBC).

Conditions

Interventions

DRUG

EO9(Apaziquone)

immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone

Sponsors & Collaborators

  • Handok Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01373398 on ClinicalTrials.gov